Skip to content

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05602376
Enrollment
3642
Registered
2022-11-02
Start date
2023-03-31
Completion date
2027-05-31
Last updated
2024-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Men, Treatment Adherence

Keywords

HIV, HIV testing, Men, U=U, Viral suppression, Treatment as Prevention, Viral load, ART uptake, Undetectable, Untransmittable

Brief summary

This study will evaluate the impact of U=U messaging and counseling on gaps in the HIV care cascade for men, including testing uptake and ART initiation (Aim 1), achieving viral suppression and retention in care (Aim 2) in two provinces in South Africa. The U=U message communicates the compelling idea that PLHIV who take ART and have an undetectable viral load (\<200 copies/mL) cannot sexually transmit HIV. Additionally, the investigators will conduct a multi-method evaluation to inform future implementation of U=U messaging interventions (Aim 3).

Detailed description

Increasing the coverage of HIV testing and treatment among people living with HIV (PLHIV) is essential for ending the global AIDS epidemic. Unfortunately, compared to women, men living with HIV (MLHIV) are less likely to know their HIV status, start anti retroviral treatment, or achieve viral suppression. Given that new HIV infections among women are driven, in part, by men's testing and treatment gaps, reducing the gender gap in testing uptake, treatment initiation and achievement of viral suppression by men must be prioritized in order to accelerate the decline in HIV incidence among women, improve men's HIV-related health outcomes and achieve the UNAIDS 95-95-95 goals by 2030. In this study, the investigators evaluate the effectiveness of Undetectable Equals Untransmittable or U=U messaging for closing the gender gap in the HIV cascade. Particularly for men, the U=U message has the potential to accelerate progress towards the 95-95-95 targets by: 1) reducing anxiety associated with HIV testing (1st 95); 2) encouraging people who test HIV positive to initiate ART (2nd 95); and 3) reducing fear of transmitting HIV to sexual partners by promoting treatment adherence to achieve viral suppression (3rd 95). While there is a growing knowledge of Treatment as Prevention (TasP)/U=U among PLWH in Western countries, the reach and penetration of the U=U message in sub-Saharan Africa has been limited and few studies have tested the impacted of accessible U=U messages on ART uptake and adherence in sub-Saharan Africa. Building on the investigators prior work on U=U messaging informed by behavioral economics and human-centered design, they propose to conduct two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2). The investigators will also conduct a multi-method evaluation to inform future implementation of U=U messaging interventions. To improve the generalizability of the findings, the study will be conducted in two provinces in South Africa (Western and Eastern Cape). If effective, the intervention can shape global HIV testing and treatment counselling guidelines and practices. The expert, multi-institutional collaborations will allow for the application of previous research findings, leverage unique implementation platforms and resources, and rapidly disseminate the findings.

Interventions

BEHAVIORALU=U testing messaging scripts

On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health

BEHAVIORALU=U adherence messaging scripts

After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
National Institutes of Health (NIH)
CollaboratorNIH
University of Pennsylvania
CollaboratorOTHER
Desmond Tutu HIV Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Aim 1: Site-testing-days will be randomised 1:1 to implement either U=U (intervention) or SoC (Control) messaging scripts for both invitation-to-test and ART initiation. Aim 2: Randomization will be stratified by the 6 study clinics, to account for possible differences in the baseline viral loads of the catchment area populations initiating ART within each clinic with individual-level randomization will be used with random block sizes.

Intervention model description

Two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2)

Eligibility

Sex/Gender
MALE
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

AIM 1: 1. male 2. aged ≥15 years 3. present a study issued invitation card to site receptionist 4. ability to provide informed consent. AIM 2: 1. cis-gender men 2. aged ≥15 years 3. newly initiating ART (i.e., treatment naïve) or re-initiating ART after 6 months of being lost-to-care 4. live in Buffalo City or Cape Town Metro Health Districts 5. provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
ART initiation among those invited to test for HIV30-day follow-up periodProportions of ART initiation among all people invited to test in each study arm over the year of Aim 1 data collection
Proportion with viral load suppression6-month visitProportions of people who have documented viral suppression at the 6-month visit in each study arm during Aim 2

Secondary

MeasureTime frameDescription
% who agree to testingBaselineProportions of testing uptake among all people invited to test in each study arm over the year of Aim 1 enrolment.
Proportion retained in care12-month visitProportions of people who have a recorded viral load at their 12-month visit in each study arm during Aim 2.

Countries

South Africa

Contacts

Primary ContactAndrew Medina-Marino, PhD
Andrew.Marino@hiv-research.org.za+27 87 821 1109

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026